19 min listen
Anti-malaria benefit of hydroxyurea in SCA, IL-22 in the treatment in lower GI acute GVHD, and FLT3-ITD changes depend on context in AML
FromBlood Podcast
Anti-malaria benefit of hydroxyurea in SCA, IL-22 in the treatment in lower GI acute GVHD, and FLT3-ITD changes depend on context in AML
FromBlood Podcast
ratings:
Length:
18 minutes
Released:
Mar 23, 2023
Format:
Podcast episode
Description
In this week’s episode we will review a study in sub-Saharan Africa where treatment of sickle cell anemia with hydroxyurea is associated with a lower incidence of malaria. New research suggests mild myelosuppression associated with hydroxyurea treatment may actually have a salutary effect. Next, a potential new treatment approach in lower GI acute GVHD. Adding an interleukin-22 therapy to corticosteroid treatment was well tolerated with a high rate of response in this very challenging patient population. Finally, common AML driver mutations such as FLT3ITD (or internal tandem duplications) orchestrate distinct transcriptional and epigenetic programs based on different genetic contexts. In the context of a common pediatric AML mutation, FLT3ITD selectively activated type I interferon signaling, suggesting a distinct therapeutic vulnerability.
Released:
Mar 23, 2023
Format:
Podcast episode
Titles in the series (100)
Season 1, Episode 7: This week’s episode will review treatment for secondary prevention of venous thromboembolism in children, a therapeutic strategy for relapsed or refractory B-cell acute lymphoblastic leukemia, Ivosidenib monotherapy in patients with newly diagnosed AML wi by Blood Podcast